A spokesperson for Cambridge, Massachusetts-based Sarepta declined to comment on the lawsuit. A Sanofi spokesperson reiterated the allegations in the complaint.
DMD is a severe degenerative genetic disorder that primarily affects boys. The U.S. Food and Drug Administration approved Sarepta's Elevidys, the first gene therapy for DMD, last year and allowed the expanded use of the drug in June.
Sarepta earned more than $200 million from sales of Elevidys last year.
According to Reuters, Genzyme's lawsuit, filed on Friday, said that its scientists invented a "highly technical, multi-phase process" for manufacturing gene therapies that Sarepta mimics to make Elevidys. It asked the court for an unspecified amount of damages for Sarepta's alleged patent infringement.
Sarepta won the dismissal of a separate patent lawsuit over Elevidys from biotech company Regenxbio earlier this year.
The case is Genzyme Corp v. Sarepta Therapeutics Inc, U.S. District Court for the District of Delaware, No. 1:24-cv-00882
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.